Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia V. Stelmakh et al. · The Lancet Oncology · 2010
Cited by 1,186 works. doi:10.1016/s1470-2045(10)70112-1
Authors
- Federico Cappuzzo
- Tudor–Eliade Ciuleanu
- Lilia V. Stelmakh
- Saulius Cicėnas
- Aleksandra Szczęsna
- Erzsébet Juhász
- Emilio Esteban
- Olivier Molinier
- Wolfram Brugger
- I. Melezínek
- Gaëlle Klingelschmitt
- Barbara Klughammer
- Giuseppe Giaccone
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer